

Dian-Sheng Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2703340/publications.pdf>

Version: 2024-02-01

18
papers

211
citations

1163117

8
h-index

1058476

14
g-index

25
all docs

25
docs citations

25
times ranked

394
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 648-654.	6.1	11
2	Prophylactic Antiviral Therapy in Low-Risk Patients infected with the Hepatitis B Virus with Solid Tumors. <i>Archives of Medical Science</i> , 2021, . .	0.9	0
3	MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669132.	3.7	8
4	MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 1218.	2.6	11
5	A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients. <i>Archives of Medical Science</i> , 2020, 16, 253-259.	0.9	0
6	Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports. <i>Translational Cancer Research</i> , 2020, 9, 388-393.	1.0	2
7	Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro. <i>International Immunopharmacology</i> , 2018, 55, 290-296.	3.8	28
8	Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors. <i>International Journal of Clinical Oncology</i> , 2018, 23, 235-242.	2.2	15
9	EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. <i>Oncology Letters</i> , 2018, 15, 6655-6665.	1.8	8
10	Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). <i>Lung Cancer</i> , 2018, 123, 7-13.	2.0	2
11	A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). <i>BMC Cancer</i> , 2017, 17, 462.	2.6	28
12	Different schedules of irinotecan administration: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2016, 5, 361-366.	1.0	3
13	LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1107-1112.	6.1	2
14	MicroRNA-377 inhibits non-small-cell lung cancer through targeting AEG-1. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13853-63.	0.5	10
15	Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report. <i>Oncology Letters</i> , 2014, 7, 805-806.	1.8	1
16	Intermittent Pneumatic Compression Pump for Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Oncology Research and Treatment</i> , 2014, 37, 170-174.	1.2	46
17	Overexpression of SAMD9 suppresses tumorigenesis and progression during non small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 157-161.	2.1	23
18	Molecular mechanisms of <sc>LKB1</sc> induced cell cycle arrest. <i>Thoracic Cancer</i> , 2013, 4, 229-233.	1.9	6